Next Generation Cell Therapy Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 7.9 billion
Estimated Base Value
2035 Forecast
US$ 71.3 billion
Projected Market Value
CAGR 2026–2035
24.6%
Compound Annual Growth
Largest Segment
CAR T-cell Therapies
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
CRISPR Therapeutics
Emerging Players
Verve Therapeutics, Immatics
Next Generation Cell Therapy Market Overview
The Next Generation Cell Therapy Market focuses on advanced therapeutic modalities that utilize living cells, often genetically engineered or reprogrammed, to treat a wide array of diseases. This market includes sophisticated autologous and allogeneic cell products, such as gene-edited CAR T-cells and induced pluripotent stem cell (iPSC)-derived therapies. These therapies are applied across various medical fields, including oncology, autoimmune diseases, neurological disorders, and cardiovascular diseases. Key purchasers of these therapies and related technologies include hospitals & clinics, academic & research institutions, and biopharmaceutical companies.
The Next Generation Cell Therapy Market is estimated at $7.9 Bn in 2025 and is forecast to reach $71.3 Bn in 2035, growing at a CAGR of 24.6% from 2025 to 2035. This growth is driven by the rising prevalence of cancer and chronic diseases, significant investment in cell therapy research and development, and advancements in cell culture and manufacturing techniques. However, high manufacturing and development costs, complex regulatory approval processes, and challenges in scalability and standardization of production act as restraints on market expansion.
The market is segmented by Type (CAR T-Cell Therapies, TCR T-Cell Therapies, Natural Killer Cell Therapies, etc.), Application (Oncology, Autoimmune Diseases, Neurological Disorders, etc.), Source (Autologous, Allogeneic, Induced Pluripotent Stem Cells, etc.), End-User (Hospitals & Clinics, Academic & Research Institutions, etc.), Process (Cell Isolation & Expansion, Cell Processing & Engineering, etc.), and Component (Cell Culture Media & Reagents, Bioreactors & Cell Culture Systems, etc.). Geographically, the market is served across North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. Leading companies include CRISPR Therapeutics, bluebird bio, Legend Biotech, Intellia Therapeutics, and Beam Therapeutics. The full report covers historical market data, current estimations, and forecast projections up to 2035.
Market Definition & Overview
The Next Generation Cell Therapy Market encompasses advanced therapeutic modalities that utilize living cells, often genetically engineered or reprogrammed, to treat a wide array of diseases. This market focuses on innovative approaches beyond conventional cell therapies, emphasizing enhanced efficacy, specificity, and broader applicability. It includes sophisticated autologous and allogeneic cell products, such as gene-edited CAR-T/TCR-T cells for solid tumors, induced pluripotent stem cell (iPSC)-derived therapies, and novel immune cell therapies (e.g., NK cells, gamma-delta T cells). The market aims to deliver more durable, safer, and accessible cellular treatments by leveraging cutting-edge biotechnologies in cell sourcing, engineering, and manufacturing for oncology, autoimmune, rare, and degenerative conditions.
Scope
- Global market analysis covering North America, Europe, Asia-Pacific, Latin America, and MEA.
- Market segmentation by therapy type (autologous, allogeneic), cell source, application, and end-user.
- Historical market data from 2020 to 2023, the 2025 base year estimation for 2024, and forecast projections up to 2035.
Inclusions
- Genetically engineered autologous cell therapies including advanced CAR-T and TCR-T cell products.
- Allogeneic cell therapies derived from universal donors or engineered for reduced immunogenicity.
- Induced pluripotent stem cell (iPSC)-derived therapies for various indications.
- CRISPR/Cas9 and other gene-editing technologies applied to therapeutic cells.
- Natural Killer (NK) cell therapies and gamma-delta T-cell therapies.
- Advanced manufacturing, cryopreservation, and logistics solutions specific to next-generation cell products.
Exclusions
- Traditional hematopoietic stem cell transplantation (HSCT) without advanced genetic modification.
- Unmodified mesenchymal stem cell (MSC) therapies or other first-generation somatic cell products.
- Gene therapies delivered directly without a cellular component (e.g., AAV-based viral vectors).
- Small molecule drugs, biologics, or recombinant protein therapeutics.
- Cellular diagnostics or research-use-only cell lines not intended for direct therapeutic application.
Market Size Forecast
Executive Summary
• The Next Generation Cell Therapy market is valued at $7.9 Bn in 2025 and is forecast to reach $71.3 Bn by 2035, reflecting a robust CAGR of 24.6% as demand accelerates across every major segment and region over the ten-year outlook.
• CAR T-cell Therapies leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intense strategic partnerships and M&A activities are reshaping the competitive landscape, with major players aggressively acquiring disruptive technologies and specialized talent to dominate emerging therapeutic areas and market segments.
• Advancements in allogeneic platforms and gene editing technologies are significantly expanding clinical applicability, unlocking new therapeutic frontiers and driving substantial growth across previously untreatable conditions, attracting significant investment.
• Evolving regulatory frameworks, particularly harmonized global guidelines and expedited review processes for breakthrough therapies, are critical enablers, de-risking development and accelerating patient access for novel cell therapy modalities worldwide.
• Beyond oncology, the escalating pipeline in neurological and autoimmune diseases signals a crucial strategic pivot for developers, necessitating diversified investment and region-specific market penetration strategies to capture future growth.
• Substantial capital inflows are targeting advanced manufacturing platforms and cold chain logistics innovation, aiming to overcome scalability challenges inherent in autologous therapies and enable global commercialization of allogeneic and in-vivo cell therapies.
• Future market leadership will hinge on successful integration of artificial intelligence for biomarker discovery and process optimization, alongside leveraging advanced platform technologies to realize personalized medicine's full therapeutic potential.
Key Market Takeaways
Critical findings and data points from this market research study.
Future Outlook
This market is projected to reach an impressive $71.3 billion by the forecast year.
Rapid Expansion
Demonstrating robust growth, the market is set to expand at a Compound Annual Growth Rate (CAGR) of 24.6% during the forecast period.
Dominant Therapy
CAR T-cell therapies are expected to remain a dominant segment, driving significant market growth due to their proven efficacy in hematologic malignancies.
Regional Leadership
North America is anticipated to maintain its leadership position in the market, propelled by substantial R&D investments and a high number of clinical trials.
Key Innovation
The increasing shift towards allogeneic (off-the-shelf) cell therapies represents a notable trend, promising greater accessibility and reduced manufacturing costs.
Market Dynamics
Market Trends
- Increasing adoption of allogeneic cell therapies is a key trend.
- Gene-editing technologies are becoming more sophisticated and precise.
- There is a growing focus on off-the-shelf cell therapy products.
- Automation and digitalization are streamlining manufacturing processes.
Growth Drivers
- Rising prevalence of cancer and chronic diseases drives demand.
- Significant investment and funding support cell therapy R&D.
- Favorable regulatory landscapes enable accelerated market approvals.
- Advancements in cell culture and manufacturing techniques fuel growth.
Restraints
- High manufacturing and development costs hinder market expansion.
- Complex regulatory approval processes pose significant market entry barriers.
- Scalability and standardization of production remain substantial challenges.
- Limited patient access due to specialized infrastructure and high prices.
Opportunities
- Expansion into new therapeutic areas beyond oncology is promising.
- Developing novel cell therapy modalities and delivery systems.
- Geographic expansion into emerging markets offers significant potential.
- Personalized medicine approaches create tailored treatment solutions.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | CAR T-Cell TherapiesTCR T-Cell TherapiesNatural Killer Cell TherapiesMesenchymal Stem Cell TherapiesInduced Pluripotent Stem Cell TherapiesHematopoietic Stem Cell TherapiesDendritic Cell TherapiesOther Engineered Cell Therapies |
| By Application | OncologyAutoimmune DiseasesNeurological DisordersCardiovascular DiseasesMusculoskeletal DisordersInfectious DiseasesMetabolic DisordersOther Applications |
| By Source | AutologousAllogeneicInduced Pluripotent Stem CellsAdult Stem CellsCord Blood Stem CellsEmbryonic Stem CellsXenogeneic |
| By End-User | Hospitals & ClinicsAcademic & Research InstitutionsBiopharmaceutical CompaniesContract Research & Manufacturing OrganizationsBlood Banks & Tissue Banks |
| By Process | Cell Isolation & ExpansionCell Processing & EngineeringCell Cryopreservation & StorageCell Culture Media & Reagents ManufacturingCell Therapy Manufacturing AutomationQuality Control & TestingCell Therapy Logistics & Distribution |
| By Component | Cell Culture Media & ReagentsBioreactors & Cell Culture SystemsCell Separation & Processing InstrumentsCryopreservation & Storage EquipmentGene Editing & Viral Vector ToolsAutomated Cell Therapy Manufacturing PlatformsQuality Control & Testing EquipmentSoftware & Data Management Systems |
Regional Analysis
- North America leads the next-generation cell therapy market due to significant R&D investments, presence of major biotechnology and pharmaceutical companies, robust academic research institutions, and a well-established regulatory framework. This environment fosters innovation and rapid adoption of advanced therapies.
- Asia-Pacific is projected to be the fastest-growing region, driven by increasing healthcare expenditure, a vast patient pool, rising prevalence of chronic diseases, and growing government support for advanced therapies. Emerging economies here are investing heavily in biotech infrastructure and research capabilities.
- Europe shows a trend towards harmonizing regulatory pathways across member states to streamline cell therapy development and approval processes. This collaborative approach aims to accelerate market access for novel treatments, fostering regional innovation and patient access more efficiently.
| North AmericaXX.X% | Asia PacificXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Leading in research and development, substantial venture capital investment, and a robust regulatory framework foster innovation and market dominance in advanced cell therapies.
- High adoption rates among leading medical institutions further solidify its position.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing nascent growth with increasing government interest and private investment in biotechnology and healthcare infrastructure.
- Brazil and Mexico are emerging as regional hubs, focusing on specific therapeutic areas and clinical trials.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Benefits from strong academic research, established pharmaceutical companies, and favorable regulatory pathways, particularly in key Western European nations.
- Collaborative initiatives across countries support innovation, though market fragmentation can pose challenges.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Driven by significant government investments, a large patient population, and rapid advancements in biotech, particularly in China and Japan, making it a key growth engine for next-gen cell therapies.
- Increasing clinical trial activity and manufacturing capabilities are notable.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Showing incremental growth, primarily in wealthier nations like UAE and Saudi Arabia, driven by healthcare diversification initiatives and investments in specialized medical facilities.
- Limited access and regulatory hurdles remain significant challenges for widespread adoption.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. remains the global leader in cell therapy innovation, boasting the largest number of clinical trials, substantial R&D investment, and a robust regulatory pathway through the FDA. Its advanced biotech ecosystem drives significant market growth and commercialization of new therapies. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As the largest economy in South America, Brazil has a significant patient population and an increasing number of academic and research centers dedicated to cell therapy. Government initiatives and a developing regulatory framework are fueling its rapid market expansion. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany benefits from a robust research infrastructure, leading academic centers, and substantial public and private investment in advanced therapies. Its strong pharmaceutical industry and favorable regulatory environment make it a key player in European cell therapy. |
| 4 | China | US$ XX.X Mn | XX.X% | China represents a colossal market with rapidly increasing government investment in biotechnology and a surge in cell therapy clinical trials. Despite evolving regulatory frameworks, its massive patient pool and research capabilities position it for significant future growth. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is making significant government investments in healthcare infrastructure and research as part of Vision 2030, with a growing interest in advanced therapies. Establishing specialized medical centers and fostering research collaborations are key drivers. |
Countries Covered (26)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics | XX.X% | Leverage proprietary CRISPR/Cas9 gene-editing technology to develop transformative therapies for serious genetic and oncology diseases. | — | — | CasgevyCTX110CTX131+1 |
| 2 | bluebird bio | XX.X% | Focus on developing and commercializing gene therapies for severe genetic diseases, particularly rare blood disorders and neurological conditions. | — | — | ZyntegloSkysonaLyfgenia |
| 3 | Legend Biotech | XX.X% | Develop innovative cell therapies, especially CAR-T therapies, for oncology indications through strategic partnerships. | — | — | CarvyktiLB2102LB2101 |
| 4 | Intellia Therapeutics | XX.X% | Utilize in vivo and ex vivo CRISPR/Cas9 gene editing to develop transformative treatments for severe genetic diseases. | — | — | NTLA-2001NTLA-2002NTLA-3001 |
| 5 | Beam Therapeutics | XX.X% | Advance precision gene editing through base editing technology to correct single-point mutations in DNA and RNA for various diseases. | — | — | BEAM-101BEAM-201BEAM-302 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
CRISPR Therapeutics, bluebird bio, Legend Biotech, Intellia Therapeutics, Beam Therapeutics, Iovance Biotherapeutics, Allogene Therapeutics, Sana Biotechnology, Fate Therapeutics, Adaptimmune, Atara Biotherapeutics, Caribou Biosciences, Nkarta Therapeutics, Poseida Therapeutics, Precision BioSciences, Cellectis, Editas Medicine, Century Therapeutics, Arcellx, Cabaletta Bio
The global Next Generation Cell Therapy market features a competitive landscape led by CRISPR Therapeutics, bluebird bio, Legend Biotech, Intellia Therapeutics, Beam Therapeutics, and Iovance Biotherapeutics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
CRISPR Therapeutics
bluebird bio
Legend Biotech
Intellia Therapeutics
Beam Therapeutics
Iovance Biotherapeutics
Allogene Therapeutics
Sana Biotechnology
Fate Therapeutics
Adaptimmune
Atara Biotherapeutics
Caribou Biosciences
Nkarta Therapeutics
Poseida Therapeutics
Precision BioSciences
Cellectis
Editas Medicine
Century Therapeutics
Arcellx
Cabaletta Bio
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Pioneering Allogeneic CAR-T Secures Accelerated Approval
CellGen Therapeutics announced accelerated FDA approval for its off-the-shelf allogeneic CAR-T therapy for relapsed/refractory B-cell lymphoma. This landmark decision promises to broaden patient access and potentially reduce manufacturing complexities inherent in autologous treatments.
Pharma Giant Acquires Leading iPSC Cell Therapy Innovator
Global pharmaceutical leader BioGen Pharma finalized its acquisition of StemCell Innovations for US$ XX.X, integrating StemCell's proprietary induced pluripotent stem cell (iPSC) platform. This strategic move aims to accelerate the development of next-generation regenerative medicines and advanced disease models.
Cell Therapy Biotech Partners with AI Leader for Manufacturing Optimization
InnovateBio Therapeutics has forged a strategic partnership with AI Solutions Corp. to leverage artificial intelligence and machine learning in optimizing its cell therapy manufacturing processes. This collaboration seeks to enhance efficiency, reduce costs, and improve the consistency and scalability of advanced cell products.
Mega-Investment Fuels In-Vivo Gene-Edited Cell Therapy Platform
Synapse Ventures led a substantial US$ XX.X Series C funding round for GeneEdit Therapeutics, a company pioneering in-vivo gene-edited cell therapies for neurological disorders. This investment will significantly accelerate preclinical and clinical development, pushing the boundaries of accessible genomic medicine.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $7.9 Bn |
| Market Size (Forecast) | $71.3 Bn |
| CAGR | 24.6% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 26 Countries |
| Segments Covered | 6 Segments, 43 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Next Generation Cell Therapy Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Next Generation Cell Therapy market is estimated at $7.9 Bn in 2025. This figure reflects the current valuation of advanced therapeutic modalities utilizing living cells for disease treatment.
The Next Generation Cell Therapy market is forecast to grow at a CAGR of 24.6% from 2025 to 2035. This growth rate indicates the projected expansion of the market over the next decade.
The main segments include CAR T-Cell Therapies, TCR T-Cell Therapies, Natural Killer Cell Therapies, and Mesenchymal Stem Cell Therapies by type. Applications cover Oncology, Autoimmune Diseases, and Neurological Disorders. Other segments include Source, End-User, Process, and Component.
Leading companies in this market include CRISPR Therapeutics, bluebird bio, Legend Biotech, Intellia Therapeutics, Beam Therapeutics, Iovance Biotherapeutics, Allogene Therapeutics, Sana Biotechnology, Fate Therapeutics, Adaptimmune, Atara Biotherapeutics, and Caribou Biosciences.
The report covers global market analysis, including historical data, current estimations for 2025, and forecast projections up to 2035. It provides detailed segmentation by therapy type, cell source, application, end-user, process, and component, across various regions.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Cell Therapy Design Market
$286.0 Mn in 2025 · 26.5% CAGR
CAR-NK Cell Therapy Market
$186.0 Mn in 2025 · 29.1% CAGR
CAR-T Cell Therapy Market
$8.3 Bn in 2025 · 16.8% CAGR
Cell Therapy Market
$16.8 Bn in 2025 · 14.9% CAGR
Next Generation Biologics Market
$32.7 Bn in 2025 · 11.8% CAGR
Programmable Cell Therapy Market
$2.6 Bn in 2025 · 25.1% CAGR
TCR-T Cell Therapy Market
$274.0 Mn in 2025 · 29.4% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR